Skip to main content

Table 2 Risk factors by severity n (%)

From: The age again in the eye of the COVID-19 storm: evidence-based decision making

 

Mild

Moderate

Severe

n (%)

n (%)

n (%)

Age (p = 0.046)

 < 30

0(0)

7(87.5)

1(12.5)

 30–45

3(13)

16(69.6)

4(17.4)

 45–60

12(19.7)

36(59)

13(21.3)

 60–75

9(10.1)

45(50.6)

35(39.3)

 > 75

13(17.1)

35(46.1)

28(36.8)

Gender (p = 0.049)

 Male

21(14.2)

73(49.3)

54(36.5)

 Female

16(14.7)

66(60.6)

27(24.8)

Hypertension

 No

15(12)

74(59.2)

36(28.8)

 Yes

19(15.7)

59(48.8)

43(35.5)

ACEIa intake

 No

6(8)

42(56.8)

26(35.1)

 Yes

7(20)

15(42.9)

13(37.1)

ARBb intake

 No

8(11)

37(50.7)

28(38.4)

 Yes

4(11.1)

19(52.8)

13(36.1)

Dyslipidaemia

 No

19(13.3)

84(58.7)

40(28)

 Yes

13(12.7)

49(48)

40(39.2)

Statins intake

 No

19(12.8)

88(59.1)

42(28.2)

 Yes

9(11.3)

39(48.8)

32(40)

Diabetes

 No

23(12.9)

102(57.3)

53(29.8)

 Yes

9(13.2)

33(48.5)

26(38.2)

Obesity

 No

20(12)

95(56.9)

52(31.1)

 Yes

3(8.8)

17(50)

14(41.2)

Primary Immunodeficiency

 No

27(11.6)

130(55.8)

76(32.6)

 Yes

0(0)

2(100)

0(0)

Secondary Immunodeficiency

 No

23(12.4)

103(55.7)

59(31.9)

 Yes

3(7.3)

24(58.5)

14(34.1)

Epidemiological background (p = 0.001)

 Nursing home resident

2(5.6)

19(52.8)

15(41.7)

 Live-in relative

10(19.2)

37(71.2)

5(9.6)

 Frontline worker

0(0)

11(78.6)

3(21.4)

 Community transmission

6(14.3)

16(38.1)

20(47.6)

  1. Abbreviations: ACEIa Angiotensin-converting enzyme inhibitors, ARBb Angiotensin II receptor blockers